Home/Filings/4/0000899243-21-009481

4//SEC Filing

LEVIN MARK J 4

Accession 0000899243-21-009481

CIK 0001640455other

View on SEC.gov Company Profile

Filed

Mar 2, 7:00 PM ET

Accepted

Mar 3, 6:00 PM ET

Size

16.9 KB

Accession

0000899243-21-009481

Insider Transaction Report

Form 4

Period: 2021-03-01

Jounce Therapeutics, Inc.JNCE

TEPPER ROBERT I

Director10% Owner

Transactions

Sale
Common Stock
2021-03-01$11.75/sh−1,450,000$17,037,500→ 7,750,349 total

Holdings

Common Stock
(indirect: See footnote)
3,048,780
Common Stock
(indirect: See footnote)
53,592
Common Stock
(indirect: See footnote)
54,085
Common Stock
(indirect: See footnote)
53,599

Third Rock Ventures GP II, L.P.

10% Owner

Transactions

Sale
Common Stock
2021-03-01$11.75/sh−1,450,000$17,037,500→ 7,750,349 total

Holdings

Common Stock
(indirect: See footnote)
54,085
Common Stock
(indirect: See footnote)
53,592
Common Stock
(indirect: See footnote)
53,599
Common Stock
(indirect: See footnote)
3,048,780

STARR KEVIN P

10% Owner

Transactions

Sale
Common Stock
2021-03-01$11.75/sh−1,450,000$17,037,500→ 7,750,349 total

Holdings

Common Stock
(indirect: See footnote)
3,048,780
Common Stock
(indirect: See footnote)
53,592
Common Stock
(indirect: See footnote)
53,599
Common Stock
(indirect: See footnote)
54,085

LEVIN MARK J

10% Owner

Transactions

Sale
Common Stock
2021-03-01$11.75/sh−1,450,000$17,037,500→ 7,750,349 total

Holdings

Common Stock
(indirect: See footnote)
53,599
Common Stock
(indirect: See footnote)
3,048,780
Common Stock
(indirect: See footnote)
54,085
Common Stock
(indirect: See footnote)
53,592

Third Rock Ventures II, L.P.

10% Owner

Transactions

Sale
Common Stock
2021-03-01$11.75/sh−1,450,000$17,037,500→ 7,750,349 total

Holdings

Common Stock
(indirect: See footnote)
53,592
Common Stock
(indirect: See footnote)
3,048,780
Common Stock
(indirect: See footnote)
54,085
Common Stock
(indirect: See footnote)
53,599

TRV GP II, LLC

10% Owner

Transactions

Sale
Common Stock
2021-03-01$11.75/sh−1,450,000$17,037,500→ 7,750,349 total

Holdings

Common Stock
(indirect: See footnote)
3,048,780
Common Stock
(indirect: See footnote)
54,085
Common Stock
(indirect: See footnote)
53,592
Common Stock
(indirect: See footnote)
53,599

Footnotes (5)

[F1]These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
[F2]These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Levin, Starr and Tepper. Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
[F3]The shares are directly held by Levin.
[F4]The shares are directly held by Starr.
[F5]The shares are directly held by Tepper.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Jounce Therapeutics, Inc.

CIK 0001640455

→

Entity typeother

Related Parties

filerCIK 0001180428

Filing Metadata

Form type: 4
Filed: Mar 2, 7:00 PM ET
Accepted: Mar 3, 6:00 PM ET
Size: 16.9 KB

View on SEC.gov